Variables | Univariatea | Multivariatea | ||
---|---|---|---|---|
HR (95Â % CI) | P value | HR (95Â % CI) | P value | |
Baseline characteristics | ||||
Age <70 y (vs. ≥70 y) | 0.749 (0.343–1.429) | 0.380 |  |  |
Sex, male (vs. female) | 0.634 (0.307–1.308) | 0.217 |  |  |
HCV infection (vs. other etiology) | 1.796 (0.964–3.348) | 0.065 |  |  |
Child Pugh = 5 (vs. ≥6) | 0.511 (0.271–0.962) | 0.038 |  |  |
TMN stage III (vs. IV) | 0.672 (0.357–1.264) | 0.218 |  |  |
Vascular invasion – (vs. +) | 0.355 (0.178–0.710) | 0.003 | 0.382 (0.186–0.786) | 0.009 |
Tumor size <50 mm (vs. ≥50 mm) | 0.777 (0.412–1.466) | 0.432 |  |  |
Previous curative therapy: Yes (vs. No) | 0.433 (0.226–0.829) | 0.012 |  |  |
AFP <100 (vs. ≥100) | 1.048 (0.561–1.961) | 0.954 |  |  |
DCP <1000 (vs. ≥1000) | 0.473 (0.509–0.912) | 0.025 | 0.509 (0.261–0.993) | 0.048 |
Initial dose of sorafenib 800 mg (vs. <800 mg) | 0.744 (0.388–1.426) | 0.373 |  |  |
HRQOL domain scores ≥40:b | ||||
Physical functioning | 0.956 (0.509–1.799) | 0.889 |  |  |
Role physical | 0.771 (0.416–1.429) | 0.408 |  |  |
Bodily pain | 1.582 (0.728–3.436) | 0.247 |  |  |
General health | 1.034 (0.516–2.070) | 0.926 |  |  |
Vitality | 1.534 (0.631–3.731) | 0.346 |  |  |
Social functioning | 0.395 (0.185–0.840) | 0.016 | 0.452 (0.206–0.995) | 0.049 |
Role emotional | 0.898 (0.455–1.770) | 0.755 |  |  |
Mental health | 0.833 (0.379–1.828) | 0.649 |  |  |